Tilray Brands (TLRY) Liabilities and Shareholders Equity (2017 - 2026)
Tilray Brands' (TLRY) quarterly Liabilities and Shareholders Equity came in at $2.3 billion in Q2 2026, up 12.23% YoY from $2.1 billion in Q2 2025, and up 12.21% on a QoQ basis from $2.1 billion in Q1 2026.
Tilray Brands (TLRY) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $2.3 billion in Q2 2026.
- Quarterly Liabilities and Shareholders Equity rose 12.23% year-over-year to $2.3 billion in Q2 2026, while the trailing twelve-month figure through May 2026 was $8.6 billion (down 18.46% YoY) and the FY2026 annual result came in at $2.3 billion, up 12.23% from the prior year.
- Liabilities and Shareholders Equity improved to $2.3 billion in Q2 2026, from $2.1 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $5.8 billion in Q1 2022 to a low of $2.1 billion in Q2 2025.
- A 5-year average of $4.0 billion and a median of $4.3 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity slumped 51.13% — and 2026, when it rose 12.23%.
- Tracing TLRY's Liabilities and Shareholders Equity over 5 years: stood at $5.5 billion in 2022, then retreated by 20.89% to $4.3 billion in 2023, then dropped by 3.21% to $4.2 billion in 2024, then plunged by 49.94% to $2.1 billion in 2025, then gained by 10.93% to $2.3 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $2.3 billion (Q2 2026), $2.1 billion (Q1 2026), and $2.1 billion (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 6.18 Bn |
| 10 | Tilray Brands | 513.87 Mn | 279.24 Mn | 90.52 Mn | 2.33 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 2.33 Bn |
| Feb 28, 2026 | 2.07 Bn |
| Nov 30, 2025 | 2.10 Bn |
| Aug 31, 2025 | 2.08 Bn |
| May 31, 2025 | 2.07 Bn |
| Nov 30, 2024 | 4.19 Bn |
| Aug 31, 2024 | 4.26 Bn |
| May 31, 2024 | 4.22 Bn |
| Feb 29, 2024 | 4.21 Bn |
| Nov 30, 2023 | 4.33 Bn |
| Aug 31, 2023 | 4.40 Bn |
| May 31, 2023 | 4.31 Bn |
| Feb 28, 2023 | 4.38 Bn |
| Nov 30, 2022 | 5.47 Bn |
| Aug 31, 2022 | 5.59 Bn |
| May 31, 2022 | 5.45 Bn |
| Feb 28, 2022 | 5.82 Bn |
| Nov 30, 2021 | 5.76 Bn |
| Aug 31, 2021 | 5.99 Bn |
| May 31, 2021 | 6.03 Bn |